Acadian Asset Management
CCCC icon

Acadian Asset Management’s C4 Therapeutics CCCC Stock Holding History

Acadian Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.43M Sell
1,806,199
-84,715
-4% -$290K 0.01% 651
2026
Q1 		$4.97M Buy
1,890,914
+1,233,741
+188% +$2.9M 0.01% 717
2025
Q4 		$1.25M Buy
657,173
+529,065
+413% +$1.25M ﹤0.01% 1042
2025
Q3 		$282K Sell
128,108
-11,615
-8% -$27.9K ﹤0.01% 1337
2025
Q2 		$198K Buy
139,723
+112,048
+405% +$163K ﹤0.01% 1309
2025
Q1 		$43K Buy
+27,675
New +$82.5K ﹤0.01% 1457
2024
Q3 		– Sell
-113,436
Closed -$524K – 2101
2024
Q2 		$524K Buy
113,436
+91,443
+416% +$545K ﹤0.01% 1184
2024
Q1 		$179K Sell
21,993
-147,423
-87% -$1.14M ﹤0.01% 1200
2023
Q4 		$956K Buy
169,416
+141,402
+505% +$322K ﹤0.01% 871
2023
Q3 		$51K Sell
28,014
-100,046
-78% -$305K ﹤0.01% 1428
2023
Q2 		$351K Buy
+128,060
New +$412K ﹤0.01% 1139

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Acadian Asset Management's CCCC Position: Q2 2026 in Review

Acadian Asset Management reduced its C4 Therapeutics (CCCC) stake by 4.5% in Q2 2026, selling an estimated $290K and leaving 1,806,199 shares worth $8.43M. The position accounts for 0.01% of the portfolio, ranked #651.

Acadian Asset Management first reported a position in CCCC in Q2 2023 and has held it in 11 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Acadian Asset Management held 1,806,199 shares of C4 Therapeutics worth $8.43M as of Q2 2026.
  • Acadian Asset Management sold 84,715 C4 Therapeutics shares in Q2 2026, an estimated $290K.
  • C4 Therapeutics made up 0.01% of Acadian Asset Management's portfolio in Q2 2026, its #651 holding.
  • Acadian Asset Management first reported a position in C4 Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.